MY187357A - Pharmaceutical composition comprising bisoprolol and perindoril - Google Patents

Pharmaceutical composition comprising bisoprolol and perindoril

Info

Publication number
MY187357A
MY187357A MYPI2017701538A MYPI2017701538A MY187357A MY 187357 A MY187357 A MY 187357A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY 187357 A MY187357 A MY 187357A
Authority
MY
Malaysia
Prior art keywords
bisoprolol
pharmaceutical composition
perindoril
composition
perindopril
Prior art date
Application number
MYPI2017701538A
Inventor
Fonknechten Gilles
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY187357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MY187357A publication Critical patent/MY187357A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fixed pharmaceutical composition comprising a beta blocker, bisoprolol, and an angiotensin converting enzyme inhibitor, perindopril, and use of said composition in the treatment and prevention of cardiovascular diseases and more especially arterial hypertension, stable coronary artery disease or chronic heart failure. Medicaments.
MYPI2017701538A 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril MY187357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (en) 2014-11-05 2014-11-05 PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR
PCT/FR2015/052975 WO2016071631A1 (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril

Publications (1)

Publication Number Publication Date
MY187357A true MY187357A (en) 2021-09-22

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017701538A MY187357A (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril

Country Status (24)

Country Link
EP (1) EP3215130B1 (en)
CY (1) CY1123322T1 (en)
DK (1) DK3215130T3 (en)
EA (1) EA032808B1 (en)
ES (1) ES2811904T3 (en)
FR (1) FR3027803B1 (en)
GE (2) GEP20196989B (en)
HR (1) HRP20201518T1 (en)
HU (1) HUE051947T2 (en)
LT (1) LT3215130T (en)
MA (1) MA40915B1 (en)
MX (1) MX372717B (en)
MY (1) MY187357A (en)
PH (1) PH12017500786B1 (en)
PL (1) PL3215130T3 (en)
PT (1) PT3215130T (en)
RS (1) RS60657B1 (en)
RU (1) RU2702362C2 (en)
SG (2) SG11201703550SA (en)
SI (1) SI3215130T1 (en)
TN (1) TN2017000170A1 (en)
UA (1) UA122131C2 (en)
WO (1) WO2016071631A1 (en)
ZA (1) ZA201703078B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127403A1 (en) 2021-10-20 2024-01-17 Servier Lab NEW TRIMETAZIDINE SALTS
CR20250440A (en) 2023-04-20 2025-11-25 Servier Lab Novel trimetazidine solid phases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501546B1 (en) 2002-05-03 2012-10-10 Hexal AG Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable combination medicine
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
EA201691986A1 (en) 2010-05-06 2017-03-31 СиЭйЭл ИНТЕРНЕШНЛ ЛИМИТЕД PHARMACEUTICAL COMPOSITION CONTAINING ASPIRIN AND BISOPROLOL

Also Published As

Publication number Publication date
MX372717B (en) 2020-05-26
SI3215130T1 (en) 2020-11-30
EP3215130A1 (en) 2017-09-13
MA40915B1 (en) 2020-08-31
CY1123322T1 (en) 2021-12-31
PH12017500786A1 (en) 2017-10-02
SG11201703550SA (en) 2017-06-29
FR3027803B1 (en) 2018-02-09
SG10201903656RA (en) 2019-05-30
EP3215130B1 (en) 2020-07-08
PT3215130T (en) 2020-08-26
ES2811904T3 (en) 2021-03-15
MX2017005848A (en) 2017-06-27
FR3027803A1 (en) 2016-05-06
HRP20201518T1 (en) 2020-12-11
EA032808B1 (en) 2019-07-31
HUE051947T2 (en) 2021-03-29
RS60657B1 (en) 2020-09-30
PL3215130T3 (en) 2020-11-16
GEAP201914507A (en) 2019-03-11
UA122131C2 (en) 2020-09-25
RU2702362C2 (en) 2019-10-08
LT3215130T (en) 2020-08-25
RU2017115341A (en) 2018-11-05
EA201790772A1 (en) 2017-09-29
TN2017000170A1 (en) 2018-10-19
GEP20196989B (en) 2019-07-10
DK3215130T3 (en) 2020-09-21
ZA201703078B (en) 2020-11-25
WO2016071631A1 (en) 2016-05-12
PH12017500786B1 (en) 2023-10-11
RU2017115341A3 (en) 2019-05-21

Similar Documents

Publication Publication Date Title
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP4335418A3 (en) Compositions and methods for treating pterygium
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
MX2020009780A (en) Autotaxin inhibitor compounds.
MA34019B1 (en) ARYLTRIAZOLONE RELATED TO A BIS-ARYL AND USE THEREOF
MX2021014242A (en) USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTI-DIABETIC THERAPY.
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
EP3261671A4 (en) Combination therapy for treatment of coronary artery disease
MX2018002546A (en) COMPOSITIONS THAT INCLUDE A UROLITINE COMPOUND.
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
MY195816A (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
UA118474C2 (en) (S) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
PH12017500786B1 (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
MD4763B1 (en) Pharmaceutical composition
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
PH12020500295A1 (en) Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same
Mancia et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension.
TN2018000344A1 (en) Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
LT3609486T (en) SARPOGRELATE FOR USE IN THE TREATMENT OF HEART DISEASES IN MAMMALS
PH12020500472A1 (en) Autotaxin inhibitor compounds
HK40044342A (en) New pharmaceutical use for the treatment of heart failure